Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

ABSTRACT:

Objectives

The risks and benefits of initiating antiretroviral treatment (ART) at high CD4 cell counts have not been reliably quantified. The Strategic Timing of AntiRetroviral Treatment (START) study is a randomized international clinical trial that compares immediate with deferred initiation of ART for HIV-positive individuals with CD4 cell counts above 500 cells/μL. We describe the demographics, HIV-specific characteristics and medical history of this cohort.

Methods

Data collected at baseline include demographics, HIV-specific laboratory values, prior medical diagnoses and concomitant medications. Baseline characteristics were compared by geographical region, gender and age.

Results

START enrolled 4685 HIV-positive participants from 215 sites in 35 countries. The

SUBMITTER: Sharma S 

PROVIDER: S-EPMC4341937 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature